23andMe Holding Co. Class A Common Stock (ME): Price and Financial Metrics

23andMe Holding Co. Class A Common Stock (ME): $2.93

-0.08 (-2.66%)

POWR Rating

Component Grades













ME Stock Price Chart Interactive Chart >

Price chart for ME

ME Price/Volume Stats

Current price $2.93 52-week high $13.68
Prev. close $3.01 52-week low $2.15
Day low $2.91 Volume 64,057
Day high $2.98 Avg. volume 3,261,906
50-day MA $3.36 Dividend yield N/A
200-day MA $6.63 Market Cap 1.31B

23andMe Holding Co. Class A Common Stock (ME) Company Bio

23andMe, Inc., a consumer genetics and research company, engages in developing a genetic database to unlock insights leading to the rapid discovery of new targets for drug development. It offers a crowdsourced platform that helps people to access, understand, and benefit from the human genome; access direct-to-consumer genetic testing; and give consumers personalized information about their genetic health risks, ancestry, and traits. The company was incorporated in 2006 and is based in Sunnyvale, California with an additional office in Mountain View, California.

ME Latest News Stream

Event/Time News Detail
Loading, please wait...

ME Latest Social Stream

Loading social stream, please wait...

View Full ME Social Stream

Latest ME News From Around the Web

Below are the latest news stories about 23andMe Holding Co that investors may wish to consider to help them evaluate ME as an investment opportunity.

Could The 23andMe Holding Co. (NASDAQ:ME) Ownership Structure Tell Us Something Useful?

The big shareholder groups in 23andMe Holding Co. ( NASDAQ:ME ) have power over the company. Institutions often own...

Yahoo | February 24, 2022

23andMe to Present at Citi’s 2022 Virtual Healthcare Conference

SUNNYVALE, Calif., Feb. 17, 2022 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (“23andMe”), a leading consumer genetics and research company with a mission to help people access, understand, and benefit from the human genome, announced today that management will be presenting at the Citi 2022 Virtual Healthcare Conference on February 24, 2022 at 1:15 pm Eastern Time. Interested parties can access a webcast of the presentation at the Investors section of the company website at investors.23

Yahoo | February 17, 2022

After Falling 67% in 1 Year, Is 23andMe Undervalued?

23andMe (NASDAQ: ME) investors have had a bumpy ride in the last 12 months. The company's shares are down by more than 67%, quarterly revenue growth has slumped into the single digits, and profitability remains far out of reach. Is this stock priced attractively for a purchase?

Yahoo | February 16, 2022

4 Green Flags for 23andMe's Future

As a genetic testing company, 23andMe Holding (NASDAQ: ME) is a futuristic business by default. There's nothing cooler than sending away a tube filled with your spit and getting (some of) the secrets of your genome unlocked and presented in a tidy report on your computer screen in return.

Yahoo | February 15, 2022

Is the Tech Stock Boom Over Forever?

Once high-flying stocks have continued to take a beating. One of the sectors where this has been the most apparent is in tech. In this segment of Backstage Pass recorded on Jan. 28, Fool contributors Jon Quast, Rachel Warren, Jason Hall, and Toby Bordelon talk about innovation.

Yahoo | February 14, 2022

Read More 'ME' Stories Here

ME Price Returns

1-mo -11.75%
3-mo -37.79%
6-mo -70.61%
1-year -70.61%
3-year N/A
5-year N/A
YTD -56.01%
2021 -41.73%
2020 N/A
2019 N/A
2018 N/A
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!

Page generated in 0.5264 seconds.